Hideaki Kuroda

This inventor holds 15 USPTO granted patents and 16 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 2007-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hideaki Kuroda. Retrieved from https://idiyas.com/inventor/hideaki-kuroda-ktvvtavh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 16)

% Patents Active = 66.7

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 5)

Average Co-Inventor Count = 8.7

ph-index = 4

Forward Citations = 75(Granted Patents)

Location History:

Osaka, JP (2016 - 2017)
Tokushima, JP (2007 - 2020)

Company Filing History:

15 out of 846

Otsuka Pharmaceutical Company, Limited

patents

Years Active: 2007-2020

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE48059 - Piperazine-substituted benzothiophenes for treatment of mental disorders (2020-06-22),

2. 9839637 - Piperazine-substituted benzothiophenes for treatment of mental disorders (2017-12-12),

3. 9539252 - Piperazine-substituted benzothiophene derivatives as antipsychotic agents (2017-01-10),

4. 9480686 - Piperazine-substituted benzothiophenes for treatment of mental disorders (2016-11-01),

5. 9260420 - Piperazine-substituted benzothiophene derivatives as antipsychotic agents (2016-02-16),

6. 9206167 - Piperazine-substituted benzothiophenes for treatment of mental disorders (2015-12-08),

7. 8618109 - Piperazine-substituted benzothiophenes for treatment of mental disorders (2013-12-31),

8. 8598162 - Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders (2013-12-03),

9. 8349840 - Piperazine-substituted benzothiophenes for treatment of mental disorders (2013-01-08),

10. 8129544 - 1-substituted-4-nitroimidazole compound and method for preparing the same (2012-03-06),

11. 8071600 - Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders (2011-12-06),

12. 7888362 - Piperazine-substituted benzothiophenes for treatment of mental disorders (2011-02-15),

13. 7807843 - 1-substituted-4-nitroimidazole compound and method for preparing the same (2010-10-05),

14. 7368579 - 1-substituted-4-nitroimidazole compound and process for producing the same (2008-05-06),

15. 7262212 - 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles (2007-08-28),

Title: Innovations of Hideaki Kuroda

Introduction

Hideaki Kuroda is a prominent inventor based in Tokushima, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of mental disorders. With a total of 15 patents to his name, Kuroda's work has garnered attention for its innovative approaches and potential impact on mental health treatments.

Latest Patents

One of Kuroda's latest patents involves piperazine-substituted benzothiophenes for the treatment of mental disorders. This invention provides a heterocyclic compound represented by a specific general formula. The compound is noted for its wide treatment spectrum for mental disorders, including central nervous system disorders, while also boasting no side effects and high safety.

Career Highlights

Kuroda is currently associated with Otsuka Pharmaceutical Company, Limited, where he continues to develop groundbreaking solutions in the pharmaceutical industry. His work is characterized by a commitment to improving mental health treatments through innovative chemical compounds.

Collaborations

Kuroda has collaborated with notable colleagues such as Shin Miyamura and Hiroshi Yamashita, contributing to a dynamic research environment that fosters innovation and creativity.

Conclusion

Hideaki Kuroda's contributions to the field of pharmaceuticals, particularly in mental health treatment, highlight his role as a leading inventor. His innovative patents and collaborations reflect a dedication to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.